ZSQR — Z Squared (Delaware) Share News
0.000.00%
Last trade - 00:00- $207.23m
- $191.74m
- $1.36m
Brief: Coeptis Therapeutics Regains Compliance With Nasdaq Listing
Brief: Coeptis Therapeutics Holdings Inc Files For Resale Of Up To 3.92 Million Shares By The Selling Stockholders - SEC Filing
Brief: Coeptis Therapeutics Announces Reverse Stock Split
Brief: Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Brief: Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development
Brief: Coeptis Therapeutics Holdings enters $20 mln SEPA with Yorkville
Brief: Coeptis Therapeutics Closes On $4.3 Million Of Series A Preferred Offering
Brief: Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T and SNAP-CAR NK
Brief: Coeptis Therapeutics To Pursue Phase 2 Program For Allogeneic NK Cell Therapy
Brief: Coeptis Therapeutics Holdings Receives Non-Compliance Letter From Nasdaq - SEC Filing
Brief: Coeptis Therapeutics Expands License Agreement With University Of Pittsburgh To Include Snap-Car NK Cell Technology
Brief: Coeptis Therapeutics Anticipates Receiving Top Line Data For DVX201 Trial In 1Q24
Brief: Coeptis Therapeutics Says On Aug 28, Received Letter From Nasdaq Informing Co Was Not In Compliance With Nasdaq Listing Rule 5550(B)(2) - SEC Filing
Brief: Coeptis Therapeutics Completes Exclusive License For Immuno-Oncology Platform From Deverra Therapeutics
Brief: Coeptis Therapeutics Announces Pricing Of $3.5 Mln Underwritten Offering
Brief: Coeptis Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Coeptis Therapeutics gains after CFO transition
Brief: Coeptis Therapeutics Appoints Brian Cogley As Chief Financial Officer
U.S. RESEARCH ROUNDUP-First Solar, Lockheed Martin, MSCI